List of Excipients in API CRIZOTINIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing CRIZOTINIB
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | XALKORI | crizotinib | 0069-8140 | AMMONIA | 2029-11-06 |
| Pfizer Laboratories Div Pfizer Inc | XALKORI | crizotinib | 0069-8140 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | 2029-11-06 |
| Pfizer Laboratories Div Pfizer Inc | XALKORI | crizotinib | 0069-8140 | CELLULOSE, MICROCRYSTALLINE | 2029-11-06 |
| Pfizer Laboratories Div Pfizer Inc | XALKORI | crizotinib | 0069-8140 | FERRIC OXIDE RED | 2029-11-06 |
| Pfizer Laboratories Div Pfizer Inc | XALKORI | crizotinib | 0069-8140 | FERROSOFERRIC OXIDE | 2029-11-06 |
| Pfizer Laboratories Div Pfizer Inc | XALKORI | crizotinib | 0069-8140 | GELATIN | 2029-11-06 |
| Pfizer Laboratories Div Pfizer Inc | XALKORI | crizotinib | 0069-8140 | MAGNESIUM STEARATE | 2029-11-06 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for CRIZOTINIB
Excipient focus: AMMONIA
CRIZOTINIB drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ANHYDROUS DIBASIC CALCIUM PHOSPHATE
CRIZOTINIB drug variants containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
CRIZOTINIB drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
CRIZOTINIB drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
CRIZOTINIB drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
CRIZOTINIB drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
CRIZOTINIB drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POTASSIUM HYDROXIDE
CRIZOTINIB drug variants containing POTASSIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing POTASSIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
CRIZOTINIB drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
CRIZOTINIB drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
CRIZOTINIB drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A
CRIZOTINIB drug variants containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
CRIZOTINIB drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | crizotinib | 0069-8140 |
| >Company | >Ingredient | >NDC |
CRIZOTINIB drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch